Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
Roche Diagnostics Corp. in Indianapolis ranks 89th on the magazine’s latest “Best Companies to Work For” list and was the only Indiana-based company selected.
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
Roche Diagnostics Corp. plans to eliminate about 80 information technology jobs at its Indianapolis-area campus over the next two years, the company said Thursday morning.
Roche Diagnostics Corp.’s North American business, which is headquartered in Indianapolis, posted a 4-percent boost in sales last year on the strength of its fluid analyzer business unit, even though its diabetes sales fell.
The OK for a new blood glucose monitor comes more than two years after FDA officials declined to approve a previous version of the Nano, which in rare cases generated inflated blood sugar readings because it did not distinguish properly between the sugars glucose and maltose.
It’s hard to believe now, but as recently as two years ago, Indianapolis was close to losing its 15th-largest employer. Roche Diagnostics Corp. was looking seriously at moving its 2,900-employee North American headquarters out of Indianapolis.
A Hamilton Superior Court judge awarded damages to the local supermarket chain in a soured sublease deal it signed with Roche Diagnostics in March 2008.
Roche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the day.
Executives at Roche Diagnostics expect the wave of austerity measures being taken by western governments—including the United States—to as much as double its sales of fluid- and DNA-based tests in the next three years.
New drug for metastatic melanoma packaged with genetic test should help Roche sell more of its cobas 4800 laboratory testing systems.
Swiss health care giant Roche Holding AG has selected its diagnostics division in Indianapolis as the site for a new North America human resources center, a move that will add 50 employees to its local operations.
Roche Diagnostics Corp. landed an $11.4 million contract to provide laboratory testing services at military hospitals in the Washington, D.C., area.
Roche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market for automated cervical cancer tests.
Delays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring a key software vendor.
Roche Diagnostics Corp. is expanding one of its Indianapolis manufacturing plants to keep up with growing sales of its leading brand of blood glucose monitors.
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
The Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
Terms of the deal, announced on Wednesday, call for Roche to acquire all the assets associated with Medical Automation Systems Inc.’s point-of-care information technology connectivity system.
